just in case someone missed this important tweet,
Post# of 1418
https://twitter.com/G_Commish/status/1552655451744919554
"No. Tollovid makes money, is commercial, so not a resource drain. But we are close to Tollovir #s needed to submit EUA so getting that over finish line is the priority before we spend on Tollovid trial with unclear approvable endpoints. Biomarkers are needed"